Array BioPharma Inc. (Nasdaq: ARRY) will regain worldwide rights to
binimetinib and receive an upfront payment of up to $85 million from
Novartis. The stock price climbed 56 cents to close at $4.47.
Array regains rights to binimetinib
December 04, 2014 at 16:10 PM EST